Clinical trials: Trop2
NSCLC
SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line Treatment
This is a Phase II clinical study to evaluate the efficacy and safety of SHR-A1921 conbined with adebrelimab in advanced NSCLC who failed the previous first-line standard therapy.
- Trial name
- NCT06480136
- Testing
- SHR-A1921 injection and adebrelimab injection
- Volunteers
- 32 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Oral Cavity Squamous Cell Carcinoma, Saliva Altered
Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients
According to the World Health Organization, oral cancer (OC) is the eighth most common cancer in the world with a five year survival rate of 50%.
- Conditions
- Oral Cavity Squamous Cell Carcinoma, Saliva Altered, Precancerous Lesions
- Trial name
- OCSALTM (NCT03529604)
- Testing
- Saliva sampling, ELISA, HPLC
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Zagreb
Locally Advanced or Metastatic Urothelial Carcinoma
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.
- Trial name
- NCT05327530
- Testing
- Avelumab, Sacituzumab Govitecan (SG), M6223
- Where
- 98 sites in United States, Australia and 10 more
- Volunteers
- 256 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Breast Cancer
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
- Trial name
- ASSET (NCT05143229)
- Testing
- Alpelisib, Sacituzumab govitecan
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Kansas Medical Center
HER2 Positive OR TROP2 Positive Non-Small Cell Lung Cancer
Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids
A case-control study was conducted to evaluate the efficacy and mechanism of action of antibody-drug conjugates (ADCs) in lung cancer, utilizing patient-derived organoid (PDO)-immune co-cultures.
- Trial name
- NCT07610616
- Testing
- Antibody-drug conjugate (ADC) combination therapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Lung Cancer, Lung Diseases
Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer
This study aims to explore the efficacy of Trop2, EpCAM-specific PET/CT imaging for noninvasive visualization of Trop2 or EpCAM expression levels in non-small cell lung cancer; and to explore the differences between novel…
- Conditions
- Lung Cancer, Lung Diseases, Lung Neoplasms, Lung Cancer Metastatic
- Trial name
- NCT07026110
- Testing
- [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)
Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy
This is a phase 2, open-label, single-arm study of sacituzumab tirumotecan in neuroendocrine prostate cancer (NEPC) with progression after platinum-based chemotherapy.
- Trial name
- STOP-NEPC (NCT07639086)
- Testing
- Sacituzumab Tirumotecan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University
Breast Cancer
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not…
- Trial name
- NCT05374512
- Testing
- Dato-DXd, Paclitaxel, Nab-paclitaxel
- Where
- 228 sites in United States, Argentina and 21 more
- Volunteers
- 644 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors
This is an first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK146D1 for injection in advanced solid tumors.
- Trial name
- NCT06929663
- Testing
- AK146D1 for injection
- Where
- Australia
- Volunteers
- 48 people
- Sponsor
- Akeso
Metastatic Breast Cancer
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
The goal of this study is to compare the study drug, sacituzumab govitecan-hziy, versus doctors' treatment of choice in participants with HR+/HER2- metastatic breast cancer (MBC) who have failed at least 2 prior chemotherapy…
- Trial name
- NCT04639986
- Testing
- Sacituzumab Govitecan-hziy, Eribulin Mesylate Injection, Capecitabine Oral Product
- Where
- 43 sites in China, South Korea and 1 more
- Volunteers
- 331 people
- Sponsor
- Gilead Sciences
Solid Tumor (Phase I)
This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer.
The Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of BD200 in adult participants with advanced solid cancers.
- Trial name
- NCT07797907
- Testing
- BD200
- Volunteers
- 110 people
- Sponsor
- Biolojic Design Ltd.
Endometrial Carcinoma
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.
- Trial name
- NCT04251416
- Testing
- Sacituzumab Govitecan
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Solid Tumors
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
To find the recommended dose of TROP2- CAR-NK cells that can be given to participants with advanced forms of solid tumors.
- Trial name
- NCT06066424
- Testing
- Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer
This is a Phase I/II study evaluating the intraperitoneal delivery of TROP2 CAR/IL-15 TGFBR2 KO NK cells in combination with oral belzutifan (120 mg daily) for patients with recurrent, locally advanced, unresectable and…
- Trial name
- NCT07377526
- Testing
- TGFBR2 KO CAR27/IL-15 NK cells
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
- Trial name
- NCT06953089
- Testing
- DB-1311/BNT324, BNT327, DB-1305/BNT325
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 450 people
- Sponsor
- DualityBio Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
A Phase I-II, First-in-Human Study of SKB264 (Sac-TMT; MK-2870) in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies.
- Conditions
- Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
- Trial name
- MK-2870-001 (NCT04152499)
- Testing
- SKB264
- Where
- 109 sites in United States, Canada and 4 more
- Volunteers
- 1,410 people
- Sponsor
- Klus Pharma Inc.
Urothelial Cancer, Non-small Cell Lung Cancer
A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]
This clinical trial is designed to assess the safety, tolerability, and antitumor activity of Datopotamab Deruxtecan (Dato-DXd) combined with other anticancer agents or as monotherapy in participants with solid tumors.
- Trial name
- NCT07890714
- Testing
- Dato-DXd, Enfortumab Vedotin (EV), Pembrolizumab
- Where
- Taiwan
- Volunteers
- 268 people
- Sponsor
- Daiichi Sankyo
Breast Cancer
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with…
- Trial name
- NCT06103864
- Testing
- Dato-DXd, Durvalumab, Paclitaxel
- Where
- 318 sites in United States, Argentina and 22 more
- Volunteers
- 625 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2).
- Trial name
- NCT05941507
- Testing
- LCB84, Anti-PD-1 monoclonal antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- LigaChem Biosciences, Inc.
Breast Cancer, Sentinel Lymph Node
Trop2-targeting NIR-II Molecular Probe for Breast Cancer Precise Surgery
Positive surgical margins are closely associated with local recurrence in breast-conserving surgery (BCS). Meanwhile, accurately assessing sentinel lymph node (SLN) metastasis is crucial for determining the extent of axillary…
- Conditions
- Breast Cancer, Sentinel Lymph Node, Margins of Excision
- Trial name
- NIR-II (NCT06713681)
- Testing
- TTP-ICG incubation solution
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Yunnan Cancer Hospital